Varicella complications requiring hospitalisation Australian Paediatric Surveillance Unit				
Please ring Prof		5 1415 if you wish to discuss th	is questionnaire.	
REPORTING CLINICIAN	-			
1. APSU Dr Code/Name		2. Month/Yea	r of Report/	
 Date questionnaire complete 				
PATIENT		.,		
4. First 2 letters of first name		5. First 2 letters of su		
 6. Date of Birth 				
7. Sex		8. Post code		
 9. Date of diagnosis] year		
10. Birth weightgram				
11. Gestational age at birth	. ,	(nown)		
12. Country of Birth	· · ·	Other Specify		
13. Mother's country of birth		Other Specify	 рк	
14. Father's country of birth		Other Specify	Ш DК	
15. Is the child of Aboriginal or			D	
If this patient is primarily cared the other physician's If no other report is	I for by another phys name and complete received for this ch p the patient's name	-	further information.	
· · · ·	question by ticking the	e appropriate box or writing y	our response in the space provided.	
Section A: Diagnosis and Histor	у			
16. How was varicella diagnosed?		ory Both		
17. If laboratory which tests were + Culture PCR E	-ve? (tick all that apply	y)		
18. Were vesicle samples collected If Yes, which laboratory?	-			
19. a. Give age when varicella illne				
b. Approximate duration of illne	ss	days		
c. Was there a history of varicella exposure?		Yes No DK		
			aibling: outbrook at appeal ata)	
d. Describe source of exposure	II KIIOWII (give details	s eg. younger uniminiumseu s	sibility, bubleak at school etc.)	
Section B: Clinical Features 20. Which complications of varicell	a infection were prese	ent? (tick all that apply)		
a. Bacteraemia / septic shock		Yes 🗌 No 🗌 DK 🗌		
b. Toxic shock / toxin mediated	disease	Yes No DK		
c. Necrotising fasciitis		Yes No DK		
d. Septic arthritis				
e. Other focal purulent collection	n	Yes No DK	If Yes, specify	
f. Encephalitis		Yes No DK		
g. Ataxia				
h. Purpura fulminans		Yes No DK		
i. Disseminated coagulopathy				
j. X-Ray evidence of pneumonia				
k. Fulminant varicella (multi-org	an involvement)			
I. Reye's Syndrome				
m. Hepatitis				

21. Is/was there conc	current or secondary infection?			
If Yes, state site of in	fection, sample type and organ	ism for all:		
Site	Sample Type	Organism		
e.g brain	e.g. CSF	e.g. Staphylococcus Aureus		
	atments related to varicella did			
a. Antiviral Treatment Yes 🗌 No 🗋 DK 🗌				
If yes which one	? Aciclovir 🗌 Famciclovir 🗌	Valaciclovir DK Other , Specify		
b. Other Yes No DK				
lf yes, please de	scribe			
Section C. Underlyi	ng medical conditions and hi	story		
23. Is the child immu	•			
	•			
24. Does the child have an underlying skin disorder? (eg eczema) Yes 🗌 No 🗌 DK 🗌				
25. Has the child any chronic illness that might increase the risk of varicella complications? (eg. Asthma, malnutrition)				
		Yes No DK		
	noke? Yes 🗌 No 🗌 DK 🗌			
27. Had the child been vaccinated against varicella (live attenuated varicella vaccine)? Yes 🗌 No 🗌 DK 🗌				
If yes, when?//				
28. Is there a history of varicella illness (other than this episode) for this child? Yes No DK				
29. Has the child ever received varicella zoster immunoglobulin? Yes Ves Ves Ves Ves				
30. Affected child's birth order eg. 1/2, 2/4,/				
Section D. Severity				
	lid the child spend in hospital? .	davs/weeks		
		DK I If yes, number of days in ICU/HDU		
33. What is the patient's current status? Still hospitalised Questionnaire is finished				
		Dead 🖾 GO TO Q33a Discharged alive 🖾 GO TO Q33b		
a. If dead, was varice	ella or its complications a cause	of death? Yes 🗌 No 🗌 DK 🗌		
b. If the child was dis	charged, were there any ongoir	ng problems on discharge? Yes 🗌 No 🗌 DK 🗌		
	Place return this questions	naire in the addressed renly-naid envelope to		
Please return this questionnaire in the addressed reply-paid envelope to Dr Yvonne Zurynski, Australian Paediatric Surveillance Unit, Locked Bag 4001, Westmead, 2145, NSW				

Thank you for your assistance with this study, which has been approved by a Human Ethics Committee. The APSU is a Unit of the Royal Australasian College of Physicians (Division of Paediatrics and Child Health) and is funded by the NHMRC (Enabling Grant No. 402784), the Department of Health and Ageing, and the Faculty of Medicine at the University of Sydney.